These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38424298)

  • 21. CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events.
    Tan DS; Aw JWX; Winther M; Goh LL; Ong HY; Wee E; Liu J; Ho HK
    J Clin Pharm Ther; 2020 Feb; 45(1):52-58. PubMed ID: 31670842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Value of CYP2C19 Genetic Testing for Guiding the Antiplatelet Therapy in a Chinese Population.
    Shen DL; Wang B; Bai J; Han Q; Liu C; Huang XH; Zhang JY
    J Cardiovasc Pharmacol; 2016 Mar; 67(3):232-6. PubMed ID: 26727381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention.
    Williams AK; Klein MD; Martin J; Weck KE; Rossi JS; Stouffer GA; Lee CR
    Circ Genom Precis Med; 2019 Feb; 12(2):e002441. PubMed ID: 30779635
    [No Abstract]   [Full Text] [Related]  

  • 24. Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.
    Madan M; Abbott JD; Lennon R; So DYF; MacDougall AM; McLaughlin MA; Murthy V; Saw J; Rihal C; Farkouh ME; Pereira NL; Goodman SG;
    J Am Heart Assoc; 2022 Jun; 11(12):e024709. PubMed ID: 35699175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiplatelet Therapy and Bleeding Outcomes With CYP2C19 Genotyping.
    Coons JC; Stevenson JM; Patel A; Smith AJC; Prebehalla L; Empey PE
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221143246. PubMed ID: 36503270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial.
    Notarangelo FM; Maglietta G; Bevilacqua P; Cereda M; Merlini PA; Villani GQ; Moruzzi P; Patrizi G; Malagoli Tagliazucchi G; Crocamo A; Guidorossi A; Pigazzani F; Nicosia E; Paoli G; Bianchessi M; Comelli MA; Caminiti C; Ardissino D
    J Am Coll Cardiol; 2018 May; 71(17):1869-1877. PubMed ID: 29540324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention.
    Mohammad AM; Al-Allawi NAS
    J Cardiovasc Pharmacol; 2018 Jun; 71(6):347-351. PubMed ID: 29554005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the
    Biswas M; Sukasem C; Khatun Kali MS; Ibrahim B
    Pharmacogenomics; 2022 Feb; 23(3):207-220. PubMed ID: 35042400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-percutaneous coronary intervention CYP2C19 genotyping in an Irish population: The potential role in identifying clopidogrel therapy-related bleeding risks.
    Soh BWT; Cusack R; Waters M; O'Connor C; Arnous S; Kiernan T
    Br J Clin Pharmacol; 2023 Aug; 89(8):2413-2422. PubMed ID: 36890711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementing a pharmacogenomic-driven algorithm to guide antiplatelet therapy among Caribbean Hispanics: a non-randomised clinical trial.
    Nuñez-Medina HJ; Monero M; Torres LM; Leal E; Gonzalez-Sepulveda L; Mayor ÁM; Renta JY; González-García ER; González A; Melin K; Scott SA; Ruaño G; Hernandez-Suarez DF; Duconge J
    BMJ Open; 2024 Sep; 14(9):e084119. PubMed ID: 39242160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia).
    Fedorinov DS; Mirzaev KB; Ivashchenko DV; Temirbulatov II; Sychev DA; Maksimova NR; Chertovskih JV; Popova NV; Tayurskaya KS; Rudykh ZA
    Drug Metab Pers Ther; 2018 Jun; 33(2):91-98. PubMed ID: 29738309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study.
    Yu L; Wang T; Bai H; Zhu W; Li Y; Wu J; Liu W; Sun L; Yu A; Li H
    BMC Cardiovasc Disord; 2021 Aug; 21(1):391. PubMed ID: 34384383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Clinical Implementation of
    Azzahhafi J; Broek WWAVD; Chan Pin Yin DRPP; Harmsze AM; van Schaik RHN; Ten Berg JM
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231210704. PubMed ID: 37899583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of individualized antiplatelet therapy, based on CYP2C19 genotyping, on platelet function in patients underwent percutaneous coronary intervention.
    Zhang M; Wang J; Zhang Y; Zhang P; Chao Y; Gao M; Hou Y
    Perfusion; 2022 Jan; 37(1):78-85. PubMed ID: 33300437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
    Cavallari LH; Franchi F; Rollini F; Been L; Rivas A; Agarwal M; Smith DM; Newsom K; Gong Y; Elsey AR; Starostik P; Johnson JA; Angiolillo DJ
    J Transl Med; 2018 Apr; 16(1):92. PubMed ID: 29642909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Lee SH; Jeong YH; Hong D; Choi KH; Lee JM; Park TK; Yang JH; Hahn JY; Choi SH; Gwon HC; Jeong MH; Kim BK; Joo HJ; Chang K; Park Y; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Kim HS; Kim MH; Lim DS; Shin ES; Song YB;
    JACC Cardiovasc Interv; 2023 Apr; 16(7):829-843. PubMed ID: 37045504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The contribution of genotype-guided selection of P2Y
    Wu Y; Yu D; Zhang L; Wu Y; Shu B; Ma L; Shi T
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1249-1259. PubMed ID: 37449992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome.
    Wang Y; Yan BP; Liew D; Lee VWY
    Pharmacogenomics J; 2018 Jan; 18(1):113-120. PubMed ID: 28117433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention.
    Ayesh BM; Al-Astal IR; Yassin MM
    Int J Clin Pharm; 2019 Feb; 41(1):96-103. PubMed ID: 30656556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.